Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation

Clinical Transplantation

Volumn 17, Issue 4, 2003, Pages 369-376

  Kode, Ravi ^a   Fa, Kosunarty ^b   Chowdhury, Shoaib ^a   Ranganna, Karthik ^a   Fyfe, Billie ^a   Stabler, Susan ^a   Damask, Anna ^a   Laftavi, Mark R ^c   Kumar, Anil Mysore ^a   Pankewycz, Oleh ^c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Acute rejection; Basiliximab; Cyclosporin; Graft survival; Kidney transplantation

Indexed keywords

ACICLOVIR; BASILIXIMAB; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGE; AGED; ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT SURVIVAL; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPERATION DURATION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CADAVER; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; RECOMBINANT FUSION PROTEINS;

EID: 0042121377     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2003.00061.x     Document Type: Article

References (26)

1. Burton RC, Cosimi AB, Colvin RB et al. Monoclonal antibodies to human T cell subsets: use for immunological monitoring and immunosuppression in renal transplantation. J Clin Immunol 1982: S3: 142S.
2. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990: 323: 1723.
3. Soulillou J-P, Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001: 72: SS89.
4. Onrust SV, Wiseman LR. Basiliximab. Drugs 1999: 57: 207.
5. Kovarik J, Wolf P, Cisterne JM et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaveric renal allografts. Transplantation 1997: 64: 1701.
6. Kovarik JM, Rawlings E, Sweny P et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996: 28: 913.
7. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monolonal antibody. Transplantation 1999: 67: 276.
8. Nashan B, Moore R, Amlot P, Schmidt A-G, Abeywickrama K, Soulillou J-P. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997: 350: 1193.
9. Mulloy LL, Wright F, Hall ML, Moore M. Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors. Trans Proc 1999: 31: 1210.
10. Sollinger H, Kaplan B, Pescovitz MD et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001: 72: 1915.
11. Ponticelli C, Yussim A, Cambi V et al. A randomized double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001: 72: 1261.
12. Kupiec-Weglinski JW, Hahn HJ, Kirkman RL et al. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. Transpl Proc 1988: 20(Suppl. 2): 207.
13. Racusen LC, Solez K, Colvin RB et al. The Banff '97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
14. Young CJ, Gaston RS. African Americans and renal transplantation: disproportionate need, limited access, and impaired outcomes. Am J Med Sci 2002: 323: 94.
15. Lee CM, Carter JT, Randall HB et al. The effect of age and prolonged cold ischemia times on the national allocation of cadaveric renal allografts. J Surg Res 2000: 91: 83.
16. Keown PA, Balshw R, Krueger H, Baladi J-F. Economic analysis of basiliximab in renal transplantation. Transplantation 2001: 71: 1573.
17. Kovarik JM, Pescovitz MD, Sollinger HW et al. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplant 2001: 15: 123.
18. Latos DL. Chronic dialysis in patients over 65. J Am Soc Nephrol 1996: 7: 637.
19. Agodoa LY, Jones CA, Held PJ. End-stage renal disease in the USA: data from the United States Renal Data System. Am J Nephrol 1966: 16: 7.
20. Basar H, Soran A, Shapiro R et al. Transplantation in recipients over the age of 60. Transplantation 1999: 67: 1191.
21. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996: 7: 158.
22. Tesi RJ, Elkhammas EA, Davies EA, Henry ML, Ferguson RM. Renal transplantation in older people. Lancet 1994: 343: 461.
23. Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001: 72: SS75.
24. Jardine A. Assessing cardiovascular risk profile of immunosuppressive agents. Transplantation 2001: 72: SS81.
25. Sivaraman P, Nussbaumer G, Landsberg D. Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Am J Kid Dis 2001: 37: 62.
26. Hirose R, Roberts JP, Quan D et al. Experience with daclizumab in liver transplantation. Transplantation 2000: 69: 307.